Reference : Many ways to resistance: How melanoma cells evade targeted therapies
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/10993/38857
Many ways to resistance: How melanoma cells evade targeted therapies
English
Kozar, Ines mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Margue, Christiane mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Rothengatter, Sonja [> >]
Haan, Claude mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Kreis, Stephanie mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
15-Feb-2019
Biochimica et Biophysica Acta - Reviews on Cancer
Elsevier
1871
2
313-322
Yes
International
0304-419X
[en] melanoma ; BRAF ; targeted therapies
[en] Melanoma is an aggressive malignancy originating from pigment-producing melanocytes. The development of targeted therapies (MAPK pathway inhibitors) and immunotherapies (immune checkpoint inhibitors) led to a substantial improvement in overall survival of patients. However, the long-term efficacy of such treatments is limited by side effects, lack of clinical effects and the rapidly emerging resistance to treatment. A number of molecular mechanisms underlying this resistant phenotype have already been elucidated. In this review, we summarise currently available treatment options for metastatic melanoma and the known resistance mechanisms to targeted therapies. A focus will be placed on “phenotype switching” as a mechanism and driver of drug resistance, together with an overview of novel approaches to circumvent resistance. A large body of recent data and literature suggests that tumour progression and phenotype switching could be better controlled and development of resistance prevented or at least delayed, by combining drugs targeting fast- and slow-proliferating cells.
Researchers
http://hdl.handle.net/10993/38857
10.1016/j.bbcan.2019.02.002

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Kozar2019.pdfPublisher postprint1.84 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.